Hernández HRJ, Forsbach SG, Treviño BJD

Language: Spanish
References: 10
Page: 57-59
PDF size: 203.13 Kb.

ABSTRACT

Introduction: The hypothyroidism is frequently observed in the first year of life of patients with Down syndrome, and the prevalence has been reported as high as 35% at 15 years old, therefore should be annually screened.
Patients and methods: The objective of this trial was to determine the prevalence hypothyroidism in patients ‹ 1 year old with Down syndrome. The TSH (tirotrophin) level was assessed bay venous blood study in a 142 Down syndrome in first year of life tiwh two determinations of TSH and free torixine hormone (FT4) before 3 months old (first period) and a one year old (second period) test.
Results: We found 40 patients with Down syndrome (29.1%) with TSH › 5.1 UI/mL and 6 › 10 UI/mL (4.3%). We found 3 great groups: the first (n = 95) with normal levees (‹ 5 UI/mL) of TSH in first and second period, the mean TSH levels were 2.60 UI/mL and 3.18 UI/mL respectively. The second group (n = 35) with a mean TSH levels of 7.99 UI/mL was sent to a Pediatric Endocrine service. And the third group (n = 12) in witch TSH at 3 months were normals but increased to abnormal at one year old with a mean TSH in first and second period of 3.28 UI/mL and 7.58 UI/mL respectively.
Conclusions: The overall prevalence of hypothyroidism in Down syndrome at first year of life was 4.3% of clinical y 29.1% sublcinical. This results support the recommendation of thyroid hormone tests need to be done twice a year of patients with Down syndrome.

REFERENCES

1. Taeusch HW, Ballard RA. Avery’s diseases of the newborn. 7th ed. Philadelphia, PA: WB Saunders; 1998. p. 1228-1230.

2. Cloherty JP, Eichenwald EC, Stark AR. Manual of neonatal care. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. p. 23-28.

3. Karlsson B, Gustafsson J, Hedov G, Ivarsson SA, Annerén G. Thyroid dysfunction in Down’s syndrome: Relation to age and thyroid autoimmunity. Arch Dis Child 1998; 79: 242-245.

4. Van Trotsenburg ASP, Vulsma T, Rutgers SL, Van Baar AL, Ridder JCD, Heymans HAS et al. The effect of thyroxine treatment started in the neonatal period on development and growth of two year-old Down syndrome children: A randomized clinical trial. J Clin Endocrinol Metab 2005; 90: 3304-3311.

5. Van Vliet G. How often should we screen children with Down’s syndrome for hypotiroidism? Arch Dis Child 2005; 90: 557-558.

6. Toscano E, Pacileo G, Limongelli G, verrengia M, Di Mita O, Di Maio S et al. Subclinical hypothyroidism and Down’s syndrome; studies on myocardial structure and function. Arch Dis Child 2003; 88: 1005-1008.

7. Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D. Cancers and immune related diseases associated with Down’s syndrome: A record linkage study. Arch Dis Child 2004; 89: 1014-1017.

8. Amnon Z, Ayala Y, Yehudith A, Zvi Z. b-adrenergic hyperresponsiveness in compensated hypothyroidism associated with Down’s syndrome. Pediatr Res 2005; 58: 66-70.

9. Van Trotsenburg ASP, Vulsma T, Van Santen HM, Cheung W, Vijlder JJM. Lower neonatal screening thyroxine concentrations in Down syndrome newborns. J Clin Endocrinol Metab 2003; 88: 1512-1515.

10. Konings CH, Van Trotsenburg ASP, Ris-Stalpers C, Vulsma T, Wiedijk BM, Vijlder JJM. Plasma thyrotropin bioactivity in Down’s syndrome children with subclinical hypothyroidism. Eur J Endocrinol 2001; 144: 1-4.